Skip to content

Study · Randomized controlled trial · n = 58 · 2018

11 results

Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study.

Dempster DW, Zhou H, Ruff VA, Melby TE, Alam J, Taylor KA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research23 Feb 2018Cited by 35 (Europe PMC)

PMID29194749 (opens in a new tab)DOI10.1002/jbmr.3350 (opens in a new tab)PepBankPUB-29194749
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In participants of the SHOTZ study, teriparatide increased remodeling-based bone formation versus zoledronic acid in all bone envelopes at 6 months.

    In plain wordsIn a bone biopsy study, teriparatide increased bone remodeling formation more than zoledronic acid in all measured bone envelopes at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRemodeling-based formation at 6 months
    Study

    n = 58

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    RBF was significantly greater after TPTD versus ZOL in all envelopes at 6 and 24 months, except the periosteal envelope at 24 months.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Teriparatide increased modeling-based formation versus zoledronic acid in all envelopes at 6 months.

    In plain wordsTeriparatide increased bone modeling formation more than zoledronic acid in all measured bone envelopes.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseModeling-based formation at 6 months
    Study

    n = 58

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    MBF was significantly greater with TPTD in all envelopes at 6 months but not at 24 months.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  3. 03HumanRandomized controlled trialEfficacy outcome

    Teriparatide increased overflow modeling-based formation versus zoledronic acid in cancellous and endocortical envelopes at 6 months.

    In plain wordsTeriparatide increased overflow bone modeling formation more than zoledronic acid in cancellous and endocortical bone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOverflow modeling-based formation at 6 months
    Study

    n = 58

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    oMBF was significantly greater at 6 months in the cancellous and endocortical envelopes with TPTD, with no significant differences at 24 months.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  4. 04HumanRandomized controlled trialEfficacy outcome

    Teriparatide increased total bone formation surface versus zoledronic acid in each envelope at 6 months.

    In plain wordsTeriparatide increased the surface of bone formation more than zoledronic acid in each measured envelope.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal bone formation surface
    Study

    n = 58

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 6 months, total bone formation surface was also significantly greater in each envelope with TPTD treatment (all p < 0.001).
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In participants of the SHOTZ study, teriparatide increased remodeling-based bone formation versus zoledronic acid in cancellous and endocortical envelopes at 24 months.

    In plain wordsIn a bone biopsy study, teriparatide increased bone remodeling formation more than zoledronic acid in cancellous and endocortical bone at 24 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous and endocortical remodeling-based formation at 24 months
    Study

    n = 19

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    RBF was significantly greater after TPTD versus ZOL in all envelopes at 6 and 24 months, except the periosteal envelope at 24 months.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  6. 06HumanRandomized controlled trialEfficacy outcome

    Periosteal remodeling-based formation did not differ significantly between teriparatide and zoledronic acid at 24 months.

    In plain wordsOuter bone remodeling formation did not differ significantly between teriparatide and zoledronic acid.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePeriosteal remodeling-based formation at 24 months
    Study

    n = 19

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    RBF was significantly greater after TPTD versus ZOL in all envelopes at 6 and 24 months, except the periosteal envelope at 24 months.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  7. 07HumanRandomized controlled trialEfficacy outcome

    Modeling-based formation did not differ significantly between teriparatide and zoledronic acid at 24 months.

    In plain wordsBone modeling formation did not differ significantly between teriparatide and zoledronic acid.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeModeling-based formation at 24 months
    Study

    n = 19

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    MBF was significantly greater with TPTD in all envelopes at 6 months but not at 24 months.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  8. 08HumanRandomized controlled trialEfficacy outcome

    Overflow modeling-based formation did not differ significantly between teriparatide and zoledronic acid at 24 months.

    In plain wordsOverflow bone modeling formation did not differ significantly between teriparatide and zoledronic acid.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOverflow modeling-based formation at 24 months
    Study

    n = 19

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    oMBF was significantly greater at 6 months in the cancellous and endocortical envelopes with TPTD, with no significant differences at 24 months.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In the teriparatide group, remodeling-based formation did not change significantly in any envelope from 6 to 24 months.

    In plain wordsWith teriparatide, bone remodeling formation did not change significantly between the two biopsies.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeRemodeling-based formation over time
    Study

    n = 10

    Comparator
    Month 6
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    For within-group comparisons from 6 to 24 months, no statistically significant changes were observed in RBF, MBF, or oMBF in any envelope for either the TPTD or ZOL treatment groups.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In the teriparatide group, modeling-based formation did not change significantly in any envelope from 6 to 24 months.

    In plain wordsWith teriparatide, bone modeling formation did not change significantly between the two biopsies.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeModeling-based formation over time
    Study

    n = 10

    Comparator
    Month 6
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    For within-group comparisons from 6 to 24 months, no statistically significant changes were observed in RBF, MBF, or oMBF in any envelope for either the TPTD or ZOL treatment groups.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In the teriparatide group, overflow modeling-based formation did not change significantly in any envelope from 6 to 24 months.

    In plain wordsWith teriparatide, overflow bone modeling formation did not change significantly between the two biopsies.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOverflow modeling-based formation over time
    Study

    n = 10

    Comparator
    Month 6
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    For within-group comparisons from 6 to 24 months, no statistically significant changes were observed in RBF, MBF, or oMBF in any envelope for either the TPTD or ZOL treatment groups.
    2 context sentences
    Summary · context
    The study included a 12-month primary study period, with treatment (TPTD 20 μg/d by subcutaneous injection or ZOL 5 mg/yr by intravenous infusion) randomized and double-blind until the month 6 biopsy
    Summary · context
    A second biopsy (TPTD, n = 10; ZOL, n = 9) was collected from the contralateral side at month 24.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.